Association between Maternal HIV and Adverse Birth Outcomes in the Era of Universal Antiretroviral Therapy in Malawi.

IF 2.2 3区 医学 Q3 IMMUNOLOGY
Nginache Nampota-Nkomba, Andrea Buchwald, Osward M Nyirenda, Felix A Mkandawire, Rhoda Masonga, Samuel Meja, Dominic Moyo, Cristiana Cairo, Miriam K Laufer
{"title":"Association between Maternal HIV and Adverse Birth Outcomes in the Era of Universal Antiretroviral Therapy in Malawi.","authors":"Nginache Nampota-Nkomba, Andrea Buchwald, Osward M Nyirenda, Felix A Mkandawire, Rhoda Masonga, Samuel Meja, Dominic Moyo, Cristiana Cairo, Miriam K Laufer","doi":"10.1097/QAI.0000000000003685","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We evaluated the relationship between maternal HIV and birth outcomes in pregnant women.</p><p><strong>Setting: </strong>Primary health care facilities in Malawi.</p><p><strong>Methods: </strong>In this prospective cohort study, pregnant women attending their first antenatal care (ANC) visit between 20-36 weeks gestation were categorized by HIV status. Women living with HIV were grouped by HIV viral load at ANC and delivery (detectable >400 copies/mL), CD4+ count at delivery (low <250 cells/mm3), and ART regimen (tenofovir- and efavirenz-based ART). We evaluated low birth weight (LBW, <2500g), preterm birth (PTB, <37 weeks gestation), small for gestational age (SGA, <10th percentile for gestational age), fetal death (pregnancy loss >28 weeks gestation), and perinatal death (<7 days) at delivery using multivariate log-binomial regression.</p><p><strong>Results: </strong>We enrolled 1208 pregnant women (633 and 575 living with and without HIV, respectively) from 2018-2022. HIV was significantly associated with increased risk of fetal or perinatal death (adjusted risk ratio (aRR) 2.09, 95% CI 1.21, 3.70), LBW (aRR 1.88, 95% CI 1.30, 2.76), and PTB (aRR 1.49, 95% CI ( 1.07, 2.09). The strength of the association with LBW increased with increasing exposure to viral load, with an aRR of 2.35 (1.01, 3.99) for LBW among women with detectable viral loads throughout pregnancy. Low CD4+ count at delivery was associated with LBW. HIV was not significantly associated with SGA. Adverse birth outcomes did not differ by ART regimen.</p><p><strong>Conclusion: </strong>Maternal HIV infection is a risk factor for adverse birth outcomes and the effect is partially mitigated by viral suppression.</p>","PeriodicalId":14588,"journal":{"name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12353428/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAIDS Journal of Acquired Immune Deficiency Syndromes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAI.0000000000003685","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: We evaluated the relationship between maternal HIV and birth outcomes in pregnant women.

Setting: Primary health care facilities in Malawi.

Methods: In this prospective cohort study, pregnant women attending their first antenatal care (ANC) visit between 20-36 weeks gestation were categorized by HIV status. Women living with HIV were grouped by HIV viral load at ANC and delivery (detectable >400 copies/mL), CD4+ count at delivery (low <250 cells/mm3), and ART regimen (tenofovir- and efavirenz-based ART). We evaluated low birth weight (LBW, <2500g), preterm birth (PTB, <37 weeks gestation), small for gestational age (SGA, <10th percentile for gestational age), fetal death (pregnancy loss >28 weeks gestation), and perinatal death (<7 days) at delivery using multivariate log-binomial regression.

Results: We enrolled 1208 pregnant women (633 and 575 living with and without HIV, respectively) from 2018-2022. HIV was significantly associated with increased risk of fetal or perinatal death (adjusted risk ratio (aRR) 2.09, 95% CI 1.21, 3.70), LBW (aRR 1.88, 95% CI 1.30, 2.76), and PTB (aRR 1.49, 95% CI ( 1.07, 2.09). The strength of the association with LBW increased with increasing exposure to viral load, with an aRR of 2.35 (1.01, 3.99) for LBW among women with detectable viral loads throughout pregnancy. Low CD4+ count at delivery was associated with LBW. HIV was not significantly associated with SGA. Adverse birth outcomes did not differ by ART regimen.

Conclusion: Maternal HIV infection is a risk factor for adverse birth outcomes and the effect is partially mitigated by viral suppression.

在马拉维普遍抗逆转录病毒治疗时代孕产妇艾滋病毒和不良分娩结果之间的关联。
背景:我们评估了孕妇母体HIV与分娩结局之间的关系。环境:马拉维的初级保健设施。方法:在这项前瞻性队列研究中,在妊娠20-36周参加首次产前保健(ANC)就诊的孕妇按艾滋病毒状况进行分类。根据产前和分娩时的HIV病毒载量(可检测到的bbb400拷贝/mL)、分娩时CD4+计数(妊娠低28周)和围产期死亡对感染HIV的妇女进行分组。结果:2018-2022年,我们招募了1208名孕妇(分别为633名和575名感染HIV和未感染HIV的孕妇)。HIV与胎儿或围产期死亡风险增加显著相关(校正风险比(aRR) 2.09, 95% CI 1.21, 3.70), LBW (aRR 1.88, 95% CI 1.30, 2.76)和PTB (aRR 1.49, 95% CI(1.07, 2.09)。与LBW的相关性随着病毒载量的增加而增加,在妊娠期间可检测到病毒载量的妇女中,LBW的aRR为2.35(1.01,3.99)。分娩时CD4+计数低与低体重有关。HIV与SGA无显著相关性。不良出生结局在ART治疗方案中没有差异。结论:母体感染HIV是不良分娩结局的危险因素,病毒抑制可部分减轻其影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.80
自引率
5.60%
发文量
490
审稿时长
3-6 weeks
期刊介绍: JAIDS: Journal of Acquired Immune Deficiency Syndromes​ seeks to end the HIV epidemic by presenting important new science across all disciplines that advance our understanding of the biology, treatment and prevention of HIV infection worldwide. JAIDS: Journal of Acquired Immune Deficiency Syndromes is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic and translational science, clinical science, and epidemiology and prevention. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信